Formulation Development
SGS Introduces First Commercial Cell Sorting Service for the Biopharmaceutical Industry
SGS, the world’s leading testing, inspection and certification company, is proud to announce the launch of Germany’s first commercial cell sorting service via fluorescent-activated cell…
Jupiter Neurosciences Partners With Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Jupiter Neurosciences, Inc. recently announced a strategic partnership with Zina Biopharmaceuticals, LLC to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s…
Rentschler Biopharma Announces Strategic Realignment of its Global Business Operations
Rentschler Biopharma SE recently announced a realignment of its global business operations as part of a long-term strategic shift. As part of this realignment, Rentschler…
Northstrive Biosciences Signs Agreement for a Potential Breakthrough Obesity Therapy Targeting Fat Loss & Muscle Preservation in Combination With GLP-1
PMGC Holdings Inc. (formerly Elevai Labs Inc.) recently announced that its subsidiary, Northstrive Biosciences Inc., has executed a research agreement with a leading preclinical contract…
Ocean Biomedical Advances Malaria Vaccine Research With New NIH Funding & Expedited Development Pathway
Ocean Biomedical recently announced its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National Institutes…
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that the U.S. Food and…
Silexion Therapeutics Reports Strong Tumor Growth Reduction From Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced promising new…
Upperton Completes Build of New Sterile Manufacturing Facility
Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions, has completed the build of its new sterile manufacturing facility in Nottingham, UK. The…
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio With Issuance of Patent for Platform Technology
Sonnet BioTherapeutics Holdings, Inc recently announced that the European Patent Office (EPO) has granted Patent No. EP3583125 B1, titled Albumin Binding Domain Fusion Proteins, which covers…
Alvotech & Teva Announce Filing Acceptance of US Biologics License Applications for a Proposed Biosimilar to Simponi & Simponi Aria
Alvotech and Teva Pharmaceuticals recently announced the US FDA has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech’s proposed biosimilar to Simponi and…
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of Second-Generation TriKE for the Treatment of Hematologic Malignancies
GT Biopharma, Inc. recently announced the first patient was dosed in a Phase 1 trial evaluating GTB-3650, its second-generation TriKE, for the treatment of relapsed…
US Patent Office Granted Can-Fite Namodenoson Patent for Use as Anti-Obesity Drug
Can-Fite BioPharma Ltd. recently announced its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US patent…
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
Cartesian Therapeutics, Inc. recently announced it has received written agreement from the US FDA under the Special Protocol Assessment (SPA) process on the overall design…
Fortress Biotech Announces First Patient Dosed in Phase 2 Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
Fortress Biotech, Inc. and its majority-owned subsidiary, Helocyte, Inc. recently announced the first patient was dosed in a multicenter, placebo-controlled and randomized Phase 2 clinical…
Aliri Launches qPCR to Complement Existing Lineup of Multi-Omics Platforms
Aliri Bioanalysis, a leading provider of advanced bioanalytical and spatial biology solutions for drug developers, is pleased to announce the addition of quantitative polymerase chain…
Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus
Attovia Therapeutics recently announced the first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE)…
Incannex Healthcare Announces Positive Topline Results From Pharmacokinetics Study of an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea
Incannex Healthcare Inc. recently announced positive topline results from a completed pharmacokinetics (PK) and safety study of IHL-42X, a novel, oral fixed-dose combination of acetazolamide…
Lisata Therapeutics & WARPNINE Announce Encouraging Preliminary Results From Phase 1b/2a iLSTA Trial
Lisata Therapeutics, Inc. and WARPNINE Incorporated recently announced encouraging preliminary results from the Phase 1b/2a iLSTA trial (ACTRN12623000223639) evaluating certepetide (formerly LSTA1), Lisata's proprietary investigational…
ArriVent BioPharma Enters Exclusive License With Lepu Biopharma for an Antibody Drug Conjugate for the Treatment of Gastrointestinal Cancers
ArriVent BioPharma, Inc. recently announced it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug…
IMMvention Therapeutix Enters Strategic Collaboration With Novo Nordisk to Develop Oral Therapies
IMMvention Therapeutix, Inc. recently announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and…
